

# Enteric Healthcare Technology Co-operative

November 2013

TO ALL CLINICAL PARTNERS

Dear Colleagues

**Professor Charles Knowles**

Co-Clinical Director

NIHR Enteric HTC

NCBRSI

2 Newark Street

Whitechapel

London E1 2AT

Direct Line: 020 7882 8757

Email: [c.h.knowles@qmul.ac.uk](mailto:c.h.knowles@qmul.ac.uk)

## Re: Pump prime funding for initial feasibility studies

As part of our mission to identify and address unmet clinical need in the diagnosis and management of disorders of the gastrointestinal tract and bowel function, we are constantly seeking new ideas for medical device innovations.

I am writing to you to inform you of the opportunity to apply to NIHR Enteric HTC for pump prime funding for initial feasibility studies on potential new medical technologies within the field of digestive diseases and GI surgery. Such funding could assist with the development of proof of scientific principle with the aim of assisting progress to definitive public funding applications. We would also be pleased to receive applications which are perhaps not directly related to the GI tract but fall within the broader remit of surgical innovation.

Specifically, NIHR Enteric HTC would like to hear of new medical technology within the following themes:

- Theme 1: Stoma (e.g. innovations that reduce the need for a stoma, prevent stoma complications or improve current appliances and quality of life for ostomates);
- Theme 2: Treatments at the neural interface (e.g. implantable or transcutaneous therapies that effect neuromodulation including electroceuticals);
- Theme 3: Novel diagnostics (in-vivo or in-vitro technologies e.g. intraluminal or cross-sectional imaging; physiological measurement devices; laboratory assays);
- Theme 4: Safe and effective surgery (e.g. surgical instruments and implants, intra-operative imaging and lighting; other theatre environmental innovations).

Funding is available to staff working in NHS organisations in England with indicative funding of up to £10,000 per project per annum. Intellectual property can be protected if relevant and applications can be assessed under non-disclosure agreements. Further information is available on our website at [www.enteric.org.uk](http://www.enteric.org.uk).

I look forward to hearing from you.

Yours sincerely

Professor Charles Knowles